The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 28, 2021
Filed:
Apr. 12, 2021
Applicant:
Crispr Therapeutics Ag, Zug, CH;
Inventors:
Jonathan Alexander Terrett, Cambridge, MA (US);
Demetrios Kalaitzidis, Cambridge, MA (US);
Lawrence Klein, Cambridge, MA (US);
Assignee:
CRISPR Therapeutics AG, Zug, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C12N 15/10 (2006.01); A61K 48/00 (2006.01); C12N 5/078 (2010.01); C12N 9/22 (2006.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/001112 (2018.08); A61K 39/001138 (2018.08); A61K 48/0066 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70539 (2013.01); C07K 14/70578 (2013.01); C12N 5/0634 (2013.01); C12N 9/22 (2013.01); C12N 15/102 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 15/86 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 15/907 (2013.01);
Abstract
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.